Expectations trend
FY2028 · fiscal year ending 2028-03-31 · fmp
Steris (STE)
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$247.91+7.16%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - SpecialtiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
12.25 → 12.26 EPS · FY ending Mar 31, 2028 · 5 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 5; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for STE yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS of $11.1 to $11.3 in fiscal 2027 | A primary condition in Steris's published investment case. The stated target is EPS between $11.1 and $11.3. | Under Pressure | EPS falls below $10.5 in FY27 | Diluted EPS: $2.04 per share FY2027-Q1; GAAP. Published target: EPS between $11.1 and $11.3. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 20262.04 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-03-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
STE looks like a steady-growth healthcare business rather than a turnaround or a high-risk growth story. Its long-term thesis is intact, with robust earnings quality, stable management, and recent performance in the top half of its industry.
The valuation is tagged as justified, while the model also describes STE as cheap versus peers; the expectations gap is modest. No valuation fragility flags are present, but the evidence does not give enough detail to say exactly what growth the market assumes.
Near term, management’s fiscal 2027 revenue growth guidance of 7-8% remains reaffirmed, and first-quarter revenue grew 7% from a year earlier. Free cash flow guidance was reduced to approximately $800 million as planned capital spending rose, so cash generation is a mixed part of execution. A recent earnings beat and a new acquisition are positive events, while the evidence gives limited detail on their expected effects.
Over the next few quarters, the thesis depends on STE maintaining its guidance and converting revenue growth into strong cash flow. A guidance cut or further weakening in jobs data could weigh on cyclical healthcare businesses, while continued earnings strength and higher guidance from sector peers would support the sector backdrop.
For the next 1-3 years, STE’s long-term thesis looks intact, with growth and sector support balanced by cash flow execution and near-term economic risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 6 of 8 supplied quarters. Management reported: “Expectations for consolidated revenue growth are unchanged and include as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%.” “Adjusted earnings per diluted share are now anticipated to be in the range of $11.35 to $11.55, an increase from prior expectations of $11.10 to $11.30.”
Free cash flow of $850 million in fiscal 2027 | Free cash flow target is $850 million for 2027. | Intact | Free cash flow falls below $800 million in FY27 | Free cash flow: $279.6M FY2027-Q1; GAAP. Published target: >= $850 million FCF. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 2026279,600,000 USD · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth of 7-8% in fiscal 2027 | A primary condition in Steris's published investment case. The stated target is 7-8% YoY revenue growth. | Under Pressure | YoY revenue growth falls below 6% in FY27 | Revenue growth: 7.3% FY2027-Q1; GAAP. Published target: 7-8% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 7, 20267.303573 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 6 of 8 supplied quarters. Management reported: “Expectations for consolidated revenue growth are unchanged and include as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%.” “Adjusted earnings per diluted share are now anticipated to be in the range of $11.35 to $11.55, an increase from prior expectations of $11.10 to $11.30.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$12.18 → $12.26 · observed estimates
$6.77B → $6.78B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $12.18 | $6,765,143,797 | 5 / 6 |
| 2026-07-25 | $12.17 | $6,772,575,880 | 8 / 8 |
| 2026-07-26 | $12.18 | $6,765,143,797 | 5 / 6 |
| 2026-07-27 | $12.18 | $6,765,143,797 | 5 / 6 |
| 2026-07-28 | $12.18 | $6,765,143,797 | 5 / 6 |
| 2026-07-29 | $12.18 | $6,765,143,797 | 5 / 6 |
| 2026-07-30 | $12.17 | $6,772,575,880 | 8 / 8 |
| 2026-07-31 | $12.17 | $6,772,575,880 | 8 / 8 |
| 2026-08-01 | $12.18 | $6,765,143,797 | 5 / 6 |
| 2026-08-02 | $12.21 | $6,777,354,410 | 9 / 9 |
| 2026-08-03 | $12.18 | $6,771,448,657 | 6 / 6 |
| 2026-08-04 | $12.21 | $6,777,354,410 | 9 / 9 |
| 2026-08-05 | $12.18 | $6,771,448,657 | 6 / 6 |
| 2026-08-06 | $12.18 | $6,771,448,657 | 6 / 6 |
| 2026-08-08 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-09 | $12.24 | $6,778,759,080 | 8 / 8 |
| 2026-08-10 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-12 | $12.24 | $6,779,582,480 | 9 / 9 |
| 2026-08-13 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-14 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-15 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-16 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-17 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-18 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-19 | $12.14 | $6,772,712,750 | 5 / 6 |
| 2026-08-20 | $12.23 | $6,779,781,178 | 6 / 6 |
| 2026-08-21 | $12.23 | $6,779,781,178 | 6 / 6 |
| 2026-08-22 | $12.23 | $6,779,781,178 | 6 / 6 |
| 2026-08-23 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-24 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-25 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-26 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-27 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-28 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-29 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-30 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-08-31 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-01 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-02 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-03 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-04 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-05 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-06 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-07 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-08 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-09 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-10 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-11 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-12 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-13 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-14 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-15 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-16 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-17 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-18 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-19 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-20 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-21 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-22 | $12.25 | $6,779,781,178 | 6 / 6 |
| 2026-09-23 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-24 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-25 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-26 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-27 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-28 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-29 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-09-30 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-01 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-02 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-03 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-04 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-05 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-06 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-07 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-08 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-09 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-10 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-11 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-12 | $12.25 | $6,779,781,178 | 6 / 7 |
| 2026-10-13 | $12.25 | $6,779,288,553 | 5 / 5 |
| 2026-10-14 | $12.25 | $6,779,288,553 | 5 / 5 |
| 2026-10-15 | $12.25 | $6,779,288,553 | 5 / 5 |
| 2026-10-16 | $12.25 | $6,779,288,553 | 5 / 5 |
| 2026-10-17 | $12.25 | $6,779,288,553 | 5 / 5 |
| 2026-10-18 | $12.26 | $6,779,186,917 | 5 / 5 |
| 2026-10-19 | $12.26 | $6,779,186,917 | 5 / 5 |
| 2026-10-20 | $12.26 | $6,779,186,917 | 5 / 5 |
| 2026-10-21 | $12.26 | $6,779,186,917 | 5 / 5 |
| 2026-10-22 | $12.26 | $6,779,186,917 | 5 / 5 |
| 2026-10-23 | $12.26 | $6,779,186,917 | 5 / 5 |
| 2026-10-24 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-25 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-26 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-27 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-28 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-29 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-30 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-10-31 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-11-01 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-11-02 | $12.26 | $6,779,749,917 | 5 / 5 |
| 2026-11-03 | $12.26 | $6,779,734,689 | 5 / 5 |
| 2026-11-04 | $12.26 | $6,779,734,689 | 5 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.